SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  SHAREHOLDER ALERT: Investigation of Geron Corporation Announced by Law Offices of Howard G. Smith

[March 12, 2014]

SHAREHOLDER ALERT: Investigation of Geron Corporation Announced by Law Offices of Howard G. Smith

BENSALEM, Pa. --(Business Wire)--

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ:GERN) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning Geron's operations and financial prospects.

Geron is a clinical stage biopharmaceutical company developing first-in-class therapies for cancer. The Company's product candidate in clinical development, imetelstat, is designed to inhibit cancer cell replication in hematologic myeloid malignancies such as myelofibrosis or acute myelogenous leukemia. The investigation is related to Geron's March 12, 2014, announcement that the Company received verbal ntice from the U.S. Food and Drug Administration that Geron's Investigational New Drug application for imetelstat has been placed on full clinical hold - an order to a trial sponsor to suspend an ongoing clinical trial or delay a proposed trial - affecting all ongoing company-sponsored clinical trials.


The clinical hold affects the remaining patients in the Company's Phase 2 study in essential thrombocythemia (ET) or polycythemia vera (PV), and the remaining patients in the Company's Phase 2 study in multiple myeloma. In addition, Geron's planned Phase 2 clinical trial in myelofibrosis will likely be delayed, and other studies using imetelstat may also be placed on clinical hold by the FDA. According to the Company, "the FDA indicated that the clinical hold is due to the occurrence of persistent low-grade liver function test abnormalities observed in the Phase 2 study of imetelstat in ET/PV patients and the potential risk of chronic liver injury following long-term exposure to imetelstat."

If you purchased Geron securities between March 12, 2013 and March 11, 2014, including shares acquired in connection with the Company's January 30, 2014, Secondary Offering priced at $4.00, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.